Association between Paraoxonase-1 p.Q192R Polymorphism and Coronary Artery Disease susceptibility in the Colombian Population

References

• World Health Organization. Global Health Estimates: life expectancy and leading causes of death and disability. Global Health Estimates: life expectancy and leading causes of death and disability. 2019. Accessed June 9, 2021. https://www.who.int/data/gho/data/themes/mortality-and-global-health-estimates.
   Google Scholar
• Virani SS, Alonso A, Aparicio HJ, et al. Heart disease and stroke statistics—2021 update. Circulation. 2021;143(8):155. doi:10.1161/CIR.0000000000000950
   Web of Science ®Google Scholar
• Falk E, Nakano M, Bentzon JF, Finn AV, Virmani R. Update on acute coronary syndromes: the pathologists’ view. Eur Heart J. 2013;34(10):719–728. doi:10.1093/eurheartj/ehs411
   PubMed Web of Science ®Google Scholar
• Ponte-Negretti CI, Isea-Perez JE, Lorenzatti AJ, et al. Atherogenic Dyslipidemia in Latin America: prevalence, causes and treatment. Int J Cardiol. 2017;243:516–522. doi:10.1016/j.ijcard.2017.05.059
   PubMed Web of Science ®Google Scholar
• Lusis AJ, Mar R, Pajukanta P. Genetics of atherosclerosis. Annu Rev Genomics Hum Genet. 2004;5(1):189–218. doi:10.1146/annurev.genom.5.061903.175930
   PubMedGoogle Scholar
• Arnett DK, Baird AE, Barkley RA, et al. Relevance of genetics and genomics for prevention and treatment of cardiovascular disease. Circulation. 2007;115(22):2878–2901. doi:10.1161/CIRCULATIONAHA.107.183679
   PubMedGoogle Scholar
• Mackness M, Mackness B. Human paraoxonase-1 (PON1): gene structure and expression, promiscuous activities and multiple physiological roles. Gene. 2015;567(1):12–21. doi:10.1016/j.gene.2015.04.088
   PubMed Web of Science ®Google Scholar
• Shih DM, Xia YR, Wang XP, et al. Combined serum paraoxonase knockout/apolipoprotein E knockout mice exhibit increased lipoprotein oxidation and atherosclerosis. J Biol Chem. 2000;275(23):17527–17535. doi:10.1074/jbc.M910376199
   PubMed Web of Science ®Google Scholar
• Tward A, Xia Y-R, Wang X-P, et al. Decreased atherosclerotic lesion formation in human serum paraoxonase transgenic mice. Circulation. 2002;106(4):484–490. doi:10.1161/01.cir.0000023623.87083.4f
   PubMed Web of Science ®Google Scholar
• Zhao Y, Ma Y, Fang Y, et al. Association between PON1 activity and coronary heart disease risk: a meta-analysis based on 43 studies. Mol Genet Metab. 2012;105(1):141–148. doi:10.1016/j.ymgme.2011.09.018
   PubMed Web of Science ®Google Scholar
• Martínez-Quintana E, Rodríguez-González F, Medina-Gil JM, Garay-Sánchez P, Tugores A. Paraoxonase 1 (Q192R) gene polymorphism, coronary heart disease and the risk of a new acute coronary event. Clin Investig Arterioscler. 2017;29(1):1–6. doi:10.1016/j.arteri.2016.07.005
   PubMed Web of Science ®Google Scholar
• Liu T, Zhang X, Zhang J, et al. Association between PON1 rs662 polymorphism and coronary artery disease. Eur J Clin Nutr. 2014;68(9):1029–1035. doi:10.1038/ejcn.2014.105
   PubMed Web of Science ®Google Scholar
• Imai Y, Morita H, Kurihara H, et al. Evidence for association between paraoxonase gene polymorphisms and atherosclerotic diseases. Atherosclerosis. 2000;149(2):435–442. doi:10.1016/s0021-9150(99)00340-8
   PubMed Web of Science ®Google Scholar
• Gupta N, Singh S, Maturu VN, Sharma YP, Gill KD. Paraoxonase 1 (PON1) polymorphisms, haplotypes and activity in predicting cad risk in North-West Indian Punjabis. PLoS One. 2011;6(5):e17805. doi:10.1371/journal.pone.0017805
   PubMed Web of Science ®Google Scholar
• Hassan MA, Al-Attas OS, Hussain T, et al. The Q192R polymorphism of the paraoxonase 1 gene is a risk factor for coronary artery disease in Saudi subjects. Mol Cell Biochem. 2013;380(1–2):121–128. doi:10.1007/s11010-013-1665-z
   PubMed Web of Science ®Google Scholar
• Bounafaa A, Berrougui H, Ghalim N, et al. Association between Paraoxonase 1 (PON1) Polymorphisms and the Risk of Acute Coronary Syndrome in a North African Population. PLoS One. 2015;10(8):e0133719. doi:10.1371/journal.pone.0133719
   PubMed Web of Science ®Google Scholar
• Luu HN, Kingah PL, North K, Boerwinkle E, Volcik KA. Interaction of folate intake and the paraoxonase Q192R polymorphism with risk of incident coronary heart disease and ischemic stroke: the atherosclerosis risk in communities study. Ann Epidemiol. 2011;21(11):815–823. doi:10.1016/j.annepidem.2011.08.007
   PubMed Web of Science ®Google Scholar
• Moreno-Godínez ME, Galarce-Sosa C, Cahua-Pablo JÁ, et al. Genotypes of Common Polymorphisms in the PON1 Gene Associated with Paraoxonase Activity as Cardiovascular Risk Factor. Arch Med Res. 2018;49(7):486–496. doi:10.1016/j.arcmed.2019.02.002
   PubMed Web of Science ®Google Scholar
• de Souza-nogueira A, Camargo AE, Remondi FA, et al. Paraoxonase 1 (PON1) Q192R genotypes and their interaction with smoking strongly increase atherogenicity and the Framingham risk score. Arch Endocrinol Metab. 2016;60(5):426–435. doi:10.1590/2359-3997000000184
   PubMed Web of Science ®Google Scholar
• Gardemann A, Philipp M, Hess K, Katz N, Tillmanns H, Haberbosch W. The paraoxonase Leu-Met54 and Gln-Arg191 gene polymorphisms are not associated with the risk of coronary heart disease. Atherosclerosis. 2000;152(2):421–431. doi:10.1016/s0021-9150(99)00489-x
   PubMed Web of Science ®Google Scholar
• Ombres D, Pannitteri G, Montali A, et al. The gln-Arg192 polymorphism of human paraoxonase gene is not associated with coronary artery disease in Italian patients. Arterioscler Thromb Vasc Biol. 1998;18(10):1611–1616. doi:10.1161/01.atv.18.10.1611
   PubMed Web of Science ®Google Scholar
• Antikainen M, Murtomäki S, Syvänne M, et al. The Gln-Arg191 polymorphism of the human paraoxonase gene (HUMPONA) is not associated with the risk of coronary artery disease in Finns. J Clin Invest. 1996;98(4):883–885. doi:10.1172/JCI118869
   PubMed Web of Science ®Google Scholar
• Bouman HJ, Schömig E, van Werkum JW, et al. Paraoxonase-1 is a major determinant of clopidogrel efficacy. Nat Med. 2011;17(1):110–116. doi:10.1038/nm.2281
   PubMed Web of Science ®Google Scholar
• Rodriguez F, Mahaffey KW. Management of Patients With NSTE-ACS: a Comparison of the Recent AHA/ACC and ESC Guidelines. J Am Coll Cardiol. 2016;68(3):313–321. doi:10.1016/j.jacc.2016.03.599
   PubMed Web of Science ®Google Scholar
• Peng W, Shi X, Xu X, Lin Y. Both CYP2C19 and PON1 Q192R genotypes influence platelet response to clopidogrel by thrombelastography in patients with acute coronary syndrome. Cardiovasc Ther. 2019;2019:3470145. doi:10.1155/2019/3470145
   PubMed Web of Science ®Google Scholar
• Serebruany VL, Steinhubl SR, Berger PB, Malinin AI, Bhatt DL, Topol EJ. Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardiol. 2005;45(2):246–251. doi:10.1016/j.jacc.2004.09.067
   PubMed Web of Science ®Google Scholar
• Shuldiner AR, O’Connell JR, Bliden KP, et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA. 2009;302(8):849–857. doi:10.1001/jama.2009.1232
   PubMed Web of Science ®Google Scholar
• Sugunaraj JP, Palaniswamy C, Selvaraj DR, Chaitanya Arudra SK, Sukhija R. Clopidogrel resistance. Am J Ther. 2010;17(2):210–215. doi:10.1097/MJT.0b013e3181bdc3e4
   PubMed Web of Science ®Google Scholar
• Angulo-Aguado M, Panche K, Tamayo-Agudelo CA, et al. A Pharmacogenetic Study of CYP2C19 in Acute Coronary Syndrome Patients of Colombian Origin Reveals New Polymorphisms Potentially Related to Clopidogrel Therapy. Journal of Personalized Medicine. 2021;11(5):400. doi:10.3390/jpm11050400
   PubMed Web of Science ®Google Scholar
• Senior J, Lugo L, Acosta N, et al. Guía de práctica clínica para pacientes con diagnóstico de síndrome coronario agudo; atención inicial y revascularización. Revista Colombiana De Cardiologia. 2013;20:45–85.
   Google Scholar
• Karczewski KJ, Francioli LC, Tiao G, et al. The mutational constraint spectrum quantified from variation in 141,456 humans. Nature. 2020;581(7809):434–443. doi:10.1038/s41586-020-2308-7
   PubMed Web of Science ®Google Scholar
• González JR, Armengol L, Solé X, et al. SNPassoc: an R package to perform whole genome association studies. Bioinformatics. 2007;23(5):644–645. doi:10.1093/bioinformatics/btm025
   PubMed Web of Science ®Google Scholar
• Regieli JJ, Jukema JW, Doevendans PA, et al. Paraoxonase variants relate to 10-year risk in coronary artery disease: impact of a high-density lipoprotein-bound antioxidant in secondary prevention. J Am Coll Cardiol. 2009;54(14):1238–1245. doi:10.1016/j.jacc.2009.05.061
   PubMed Web of Science ®Google Scholar
• Marija G, Karmela B, Lada R, et al. Genetic Frequencies of Paraoxonase 1 Gene Polymorphisms in Croatian Population. Croatica Chemica Acta. 2008;81(1):101–105.
   Web of Science ®Google Scholar
• Scacchi R, Corbo RM, Rickards O, De Stefano GF. New data on the world distribution of paraoxonase (PON1 Gln 192 –> Arg) gene frequencies. Hum Biol. 2003;75(3):365–373. doi:10.1353/hub.2003.0049
   PubMed Web of Science ®Google Scholar
• Helaly MA-H, Abdel-Khalek EE-S, Abdel-Hafez HA, Soliman AW, Daoud EM, Lotfy ZF. Paraoxonase1 55 and 192 gene polymorphisms in an Egyptian population with diabetic complications. Int J Diabetes Dev Ctries. 2013;33(4):207–212. doi:10.1007/s13410-013-0146-y
   Web of Science ®Google Scholar
• Carranza Alva E, Peña Suasnábar C, Carranza Florenti A. Distribution of the Q192R polymorphism of the paraoxonase 1 gene in a population of the district of Junín (Junín region, Peru). HorizMed. 2017;17(2):22–29. doi:10.24265/horizmed.2017.v17n2.04
   Google Scholar
• Fridman O, Gariglio L, Riviere S, Porcile R, Fuchs A, Potenzoni M. Paraoxonase 1 gene polymorphisms and enzyme activities in coronary artery disease and its relationship to serum lipids and glycemia. Arch Cardiol Mex. 2016;86(4):350–357. doi:10.1016/j.acmx.2016.08.001
   PubMedGoogle Scholar
• Sen-Banerjee S, Siles X, Campos H. Tobacco Smoking Modifies Association Between Gln-Arg192 Polymorphism of Human Paraoxonase Gene and Risk of Myocardial Infarction. Arterioscler Thromb Vasc Biol. 2000;20(9):2120–2126. doi:10.1161/01.ATV.20.9.2120
   PubMed Web of Science ®Google Scholar
• Orengo-Mercado C. Frequencies of Functional Polymorphisms in Three Pharmacokinetic Genes of Clinical Interest within the Admixed Puerto Rican Population. J Pharmacogenom Pharmacoproteomics. 2013;04:01. doi:10.4172/2153-0645.1000113
   Google Scholar
• Siller-López F, Garzón-Castaño S, Ramos-Márquez ME, Hernández-Cañaveral I. Association of Paraoxonase-1 Q192R (rs662) Single Nucleotide Variation with Cardiovascular Risk in Coffee Harvesters of Central Colombia. J Toxicol. 2017;2017:6913106. doi:10.1155/2017/6913106
   PubMed Web of Science ®Google Scholar
• Karlsson H, Kontush A, James RW. Functionality of HDL: antioxidation and detoxifying effects. Handb Exp Pharmacol. 2015;224:207–228. doi:10.1007/978-3-319-09665-0_5
   PubMedGoogle Scholar
• Shih DM, Gu L, Xia Y-R, et al. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature. 1998;394(6690):284–287. doi:10.1038/28406
   PubMed Web of Science ®Google Scholar
• Hernández-Díaz Y, Tovilla-Zárate CA, Juárez-Rojop IE, et al. Effects of paraoxonase 1 gene polymorphisms on heart diseases: systematic review and meta-analysis of 64 case-control studies. Medicine. 2016;95(44):e5298. doi:10.1097/MD.0000000000005298
   PubMed Web of Science ®Google Scholar
• Bhattacharyya T, Nicholls SJ, Topol EJ, et al. Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk. JAMA. 2008;299(11):1265–1276. doi:10.1001/jama.299.11.1265
   PubMed Web of Science ®Google Scholar
• Ferré N, Tous M, Paul A, et al. Paraoxonase Gln-Arg(192) and Leu-Met(55) gene polymorphisms and enzyme activity in a population with a low rate of coronary heart disease. Clin Biochem. 2002;35(3):197–203. doi:10.1016/S0009-9120(02)00295-3
   PubMed Web of Science ®Google Scholar
• Hampe M, Mogarekar M. Paraoxonase1, its Q192R polymorphism and HDL-cholesterol in relation to intensive cardiac care unit stay in ischemic heart disease. Indian J Hum Genet. 2014;20(1):51. doi:10.4103/0971-6866.132756
   PubMedGoogle Scholar
• Bayrak A, Bayrak T, Tokgözoglu SL, et al. Serum PON-1 Activity but not Q192R Polymorphism is Related to the Extent of Atherosclerosis. JAT. 2012;19(4):376–384. doi:10.5551/jat.11320
   Google Scholar
• Munshi R, Panchal F, Chaurasia A, Rajadhyaksha G. Association between Paraoxonase 1(PON1) Gene Polymorphisms and PON1 Enzyme Activity in Indian Patients with Coronary Artery Disease (CAD). CPPM. 2019;16(3):219–229. doi:10.2174/1875692117666181227112119
   Google Scholar
• Costa LG, Cole TB, Jarvik GP, Furlong CE. Functional Genomics of the Paraoxonase (PON1) Polymorphisms: effects on Pesticide Sensitivity, Cardiovascular Disease, and Drug Metabolism. Annu Rev Med. 2003;54(1):371–392. doi:10.1146/annurev.med.54.101601.152421
   PubMedGoogle Scholar
• Lewis JP, Fisch AS, Ryan K, et al. Paraoxonase 1 (PON1) gene variants are not associated with clopidogrel response. Clin Pharmacol Ther. 2011;90(4):568–574. doi:10.1038/clpt.2011.194
   PubMed Web of Science ®Google Scholar
• Hulot J-S, Collet J-P, Cayla G, et al. CYP2C19 but not PON1 genetic variants influence clopidogrel pharmacokinetics, pharmacodynamics, and clinical efficacy in post-myocardial infarction patients. Circ Cardiovasc Interv. 2011;4(5):422–428. doi:10.1161/CIRCINTERVENTIONS.111.963025
   PubMed Web of Science ®Google Scholar
• Camps J, Joven J, Mackness B, et al. Paraoxonase-1 and clopidogrel efficacy. Nat Med. 2011;17(9):1041–1042. doi:10.1038/nm.2386
   PubMedGoogle Scholar
• Garcia A. Paraoxonase-1 Deficiency does not Influence Clopidogrel Antiplatelet Function in Mice. Cardiovasc Pharmacol. 2015;4:3. doi:10.4172/2329-6607.1000148
   Google Scholar
• Ginsberg G, Neafsey P, Hattis D, Guyton KZ, Johns DO, Sonawane B. Genetic polymorphism in paraoxonase 1 (PON1): population distribution of PON1 activity. J Toxicol Environ Health B Crit Rev. 2009;12(5–6):473–507. doi:10.1080/10937400903158409
   PubMed Web of Science ®Google Scholar
• Salzano FM, Sans M. Interethnic admixture and the evolution of Latin American populations. Genet Mol Biol. 2014;37(1 Suppl):151–170. doi:10.1590/s1415-47572014000200003
   PubMed Web of Science ®Google Scholar
• Adhikari K, Mendoza-Revilla J, Chacón-Duque JC, Fuentes-Guajardo M, Ruiz-Linares A. Admixture in Latin America. Curr Opin Genet Dev. 2016;41:106–114. doi:10.1016/j.gde.2016.09.003
   PubMed Web of Science ®Google Scholar
• Avena S, Via M, Ziv E, et al. Heterogeneity in genetic admixture across different regions of Argentina. PLoS One. 2012;7(4):e34695. doi:10.1371/journal.pone.0034695
   PubMed Web of Science ®Google Scholar
• Roest M, van Himbergen TM, Barendrecht AB, Peeters PHM, van der Schouw YT, Voorbij HAM. Genetic and environmental determinants of the PON-1 phenotype. Eur J Clin Invest. 2007;37(3):187–196. doi:10.1111/j.1365-2362.2007.01769.x
   PubMed Web of Science ®Google Scholar
• Hendricks AE, Billups SC, Pike HNC, et al. ProxECAT: proxy External Controls Association Test. A new case-control gene region association test using allele frequencies from public controls. PLoS Genet. 2018;14(10):e1007591. doi:10.1371/journal.pgen.1007591
   PubMed Web of Science ®Google Scholar
• Li Y, Lee S. Novel score test to increase power in association test by integrating external controls. Genet Epidemiol. 2021;45(3):293–304. doi:10.1002/gepi.22370
   PubMed Web of Science ®Google Scholar
• Ghouse J, Skov MW, Bigseth RS, Ahlberg G, Kanters JK, Olesen MS. Distinguishing pathogenic mutations from background genetic noise in cardiology: the use of large genome databases for genetic interpretation. Clin Genet. 2018;93(3):459–466. doi:10.1111/cge.13066
   PubMed Web of Science ®Google Scholar